We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BHC raises 2026 revenue view to $5.525-$5.625 billion and adjusted EBITDA outlook to $3.225-$3.275 billion.
Xifaxan pricing changes and inventory adjustments are expected to pressure Q4 revenue and EBITDA growth.
BHC cuts quarterly net debt by $521 million, with YTD reductions topping $1 billion amid stronger cash flow.
Bausch Health Companies Inc. (BHC - Free Report) emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.
The discussion also addressed capital allocation, Solta Medical's competitive environment, pipeline development and strategic options involving Bausch + Lomb. Management's commentary highlighted the balance between current operating momentum and challenges approaching in 2027.
Adjusted operating cash flow guidance rose to $1.6-$1.675 billion. Charhon said guidance midpoints increased by $150 million for revenue, approximately $190 million for adjusted EBITDA and $200 million for adjusted operating cash flow.
Consolidated third-quarter revenues reached $2.94 billion, exceeding the Zacks Consensus Estimate of $2.75 billion. Adjusted earnings of $1.77 per share surpassed the consensus estimate of $1.08. Consolidated adjusted EBITDA attributable to Bausch Health increased 32% to $1.305 billion.
Bausch Health Cos Inc. Price, Consensus and EPS Surprise
Charhon cautioned that fourth-quarter performance would reflect adjustments associated with Xifaxan's new Medicare pricing, effective January 2027.
Management expects gross-to-net accrual adjustments to reduce fourth-quarter revenue growth by 800 basis points and adjusted EBITDA growth by 1,400 basis points. Anticipated inventory normalization could create additional reductions of at least 300 and 500 basis points, respectively.
During questioning from Evercore ISI, Charhon quantified the accrual impact at more than $100 million. He also indicated an approximately $400-$500 million year-over-year net impact from pricing-related factors implied by the company's 2027 Xifaxan revenue outlook of approximately $2.7 billion.
BHC Sees Continued Strength Across Core Businesses
Chief executive officer Thomas Appio highlighted 14 consecutive quarters of year-over-year revenue and adjusted EBITDA growth, excluding Bausch + Lomb.
Salix revenues increased 16% to $831 million, supported by Xifaxan pricing and demand. Charhon noted that increased channel inventory also contributed to quarterly volume growth.
International revenues increased 4% organically, with momentum across Canada, Europe and Latin America. Appio emphasized established commercial infrastructure and targeted launches as opportunities to support future expansion.
Bausch Health Addresses Solta's Uneven Demand
Solta Medical reported 18% revenue growth, although organic revenues declined 4%. Charhon attributed the divergence partly to the China distributor acquisition and uneven prior-year sales patterns.
During RBC Capital Markets' questioning, Appio acknowledged softer Chinese consumer spending and increased competition from domestic and Korean aesthetics brands.
Appio also described Korea as a relatively saturated equipment market, while consumables continued growing. Charhon projected mid-single-digit organic growth for Solta in the fourth quarter, supported by business dynamics in Korea.
BHC Prioritizes Debt Reduction and Capital Allocation
The company reported a $521 million quarterly net debt reduction, bringing year-to-date reductions above $1 billion. Management attributed the progress primarily to stronger operating earnings and cash generation.
Capital allocation plans include potential early redemption of 2027 notes and up to $100 million in open-market debt repurchases. The company also authorized a $50 million share repurchase program primarily to offset anticipated equity-award dilution.
Appio emphasized disciplined investment alongside deleveraging. He identified hepatology, gastroenterology, dermatology and neuroscience as priorities for business development.
Bausch Health Discusses Pipeline and Ownership Options
An Evercore ISI analyst questioned whether Bausch Health and Bausch + Lomb could pursue a more formal combination. Appio reiterated that strategic options remain under consideration without announcing a transaction.
Management also discussed larsucosterol's Phase III development program for alcohol-associated hepatitis, maintaining its objective of regulatory approval in 2029, subject to successful development and review.
In response to questions about interim analysis, management indicated that early study termination and submission were not anticipated, favoring completion of the planned trial.
BHC Maintains Focus on Execution
Appio's closing remarks emphasized profitable growth, operational discipline and targeted portfolio investments as the company's principal priorities.
Management enters the fourth quarter with increased guidance but expects Xifaxan-related adjustments to affect near-term comparisons. Improving cash generation and managing the portfolio remain central to its approach.
What BHC's Zacks Rank and Style Scores Indicate
BHC carries a Zacks Rank #2 (Buy), indicating favorable near-term earnings estimate revision characteristics. Its Value Score of A and Growth Score of A highlight attractive valuation and growth attributes under Zacks' scoring methodology. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock also holds a VGM Score of A, combining value, growth and momentum characteristics, although its Momentum Score of D indicates weaker price-trend characteristics. The combination of a Zacks Rank #2 and favorable Value, Growth and VGM scores is consistent with Zacks' preferred screening framework.
Investors should note that the Zacks Rank can change as analysts revise their earnings estimates following the recently reported results.
View the Zacks #1 Rank List
Image: Bigstock
BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks
Key Takeaways
Bausch Health Companies Inc. (BHC - Free Report) emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised its full-year guidance while outlining anticipated headwinds from Xifaxan pricing changes and inventory adjustments.
The discussion also addressed capital allocation, Solta Medical's competitive environment, pipeline development and strategic options involving Bausch + Lomb. Management's commentary highlighted the balance between current operating momentum and challenges approaching in 2027.
BHC Raises 2026 Outlook on Operating Strength
Chief financial officer Jean-Jacques Charhon raised Bausch Health's 2026 revenue guidance, excluding Bausch + Lomb, to $5.525-$5.625 billion, representing 7%-9% annual growth. Adjusted EBITDA guidance increased to $3.225-$3.275 billion.
Adjusted operating cash flow guidance rose to $1.6-$1.675 billion. Charhon said guidance midpoints increased by $150 million for revenue, approximately $190 million for adjusted EBITDA and $200 million for adjusted operating cash flow.
Consolidated third-quarter revenues reached $2.94 billion, exceeding the Zacks Consensus Estimate of $2.75 billion. Adjusted earnings of $1.77 per share surpassed the consensus estimate of $1.08. Consolidated adjusted EBITDA attributable to Bausch Health increased 32% to $1.305 billion.
Bausch Health Cos Inc. Price, Consensus and EPS Surprise
Bausch Health Cos Inc. price-consensus-eps-surprise-chart | Bausch Health Cos Inc. Quote
Bausch Health Flags Xifaxan Pricing Pressure
Charhon cautioned that fourth-quarter performance would reflect adjustments associated with Xifaxan's new Medicare pricing, effective January 2027.
Management expects gross-to-net accrual adjustments to reduce fourth-quarter revenue growth by 800 basis points and adjusted EBITDA growth by 1,400 basis points. Anticipated inventory normalization could create additional reductions of at least 300 and 500 basis points, respectively.
During questioning from Evercore ISI, Charhon quantified the accrual impact at more than $100 million. He also indicated an approximately $400-$500 million year-over-year net impact from pricing-related factors implied by the company's 2027 Xifaxan revenue outlook of approximately $2.7 billion.
BHC Sees Continued Strength Across Core Businesses
Chief executive officer Thomas Appio highlighted 14 consecutive quarters of year-over-year revenue and adjusted EBITDA growth, excluding Bausch + Lomb.
Salix revenues increased 16% to $831 million, supported by Xifaxan pricing and demand. Charhon noted that increased channel inventory also contributed to quarterly volume growth.
International revenues increased 4% organically, with momentum across Canada, Europe and Latin America. Appio emphasized established commercial infrastructure and targeted launches as opportunities to support future expansion.
Bausch Health Addresses Solta's Uneven Demand
Solta Medical reported 18% revenue growth, although organic revenues declined 4%. Charhon attributed the divergence partly to the China distributor acquisition and uneven prior-year sales patterns.
During RBC Capital Markets' questioning, Appio acknowledged softer Chinese consumer spending and increased competition from domestic and Korean aesthetics brands.
Appio also described Korea as a relatively saturated equipment market, while consumables continued growing. Charhon projected mid-single-digit organic growth for Solta in the fourth quarter, supported by business dynamics in Korea.
BHC Prioritizes Debt Reduction and Capital Allocation
The company reported a $521 million quarterly net debt reduction, bringing year-to-date reductions above $1 billion. Management attributed the progress primarily to stronger operating earnings and cash generation.
Capital allocation plans include potential early redemption of 2027 notes and up to $100 million in open-market debt repurchases. The company also authorized a $50 million share repurchase program primarily to offset anticipated equity-award dilution.
Appio emphasized disciplined investment alongside deleveraging. He identified hepatology, gastroenterology, dermatology and neuroscience as priorities for business development.
Bausch Health Discusses Pipeline and Ownership Options
An Evercore ISI analyst questioned whether Bausch Health and Bausch + Lomb could pursue a more formal combination. Appio reiterated that strategic options remain under consideration without announcing a transaction.
Management also discussed larsucosterol's Phase III development program for alcohol-associated hepatitis, maintaining its objective of regulatory approval in 2029, subject to successful development and review.
In response to questions about interim analysis, management indicated that early study termination and submission were not anticipated, favoring completion of the planned trial.
BHC Maintains Focus on Execution
Appio's closing remarks emphasized profitable growth, operational discipline and targeted portfolio investments as the company's principal priorities.
Management enters the fourth quarter with increased guidance but expects Xifaxan-related adjustments to affect near-term comparisons. Improving cash generation and managing the portfolio remain central to its approach.
What BHC's Zacks Rank and Style Scores Indicate
BHC carries a Zacks Rank #2 (Buy), indicating favorable near-term earnings estimate revision characteristics. Its Value Score of A and Growth Score of A highlight attractive valuation and growth attributes under Zacks' scoring methodology. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock also holds a VGM Score of A, combining value, growth and momentum characteristics, although its Momentum Score of D indicates weaker price-trend characteristics. The combination of a Zacks Rank #2 and favorable Value, Growth and VGM scores is consistent with Zacks' preferred screening framework.
Investors should note that the Zacks Rank can change as analysts revise their earnings estimates following the recently reported results.